The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652 given once daily to people with excessive daytime sleepiness. Subjects will be randomized to either ABT-652 or placebo in three sequential dosing groups for a 1-week treatment period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
36
Site Reference ID/Investigator# 43241
Phoenix, Arizona, United States
Site Reference ID/Investigator# 38092
Glendale, California, United States
Site Reference ID/Investigator# 43264
San Diego, California, United States
Site Reference ID/Investigator# 40402
New York, New York, United States
Laboratory Tests
Time frame: Baseline period to end of 1-week treatment period.
ECG
Time frame: Baseline period to end of 1-week treatment period.
Adverse Events
Time frame: Baseline period till 30 days after the last dose.
Vital Signs
Time frame: Baseline period to end of 1-week treatment period.
Maintenance Wakefulness Test
Time frame: Baseline period to end of 1-week treatment period.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site Reference ID/Investigator# 38122
Durham, North Carolina, United States